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A B S T R A C T
New approaches are needed to assess the eﬀects of inhaled substances on human health. These approaches will
be based on mechanisms of toxicity, an understanding of dosimetry, and the use of in silico modeling and in vitro
test methods. In order to accelerate wider implementation of such approaches, development of adverse outcome
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pathways (AOPs) can help identify and address gaps in our understanding of relevant parameters for model input
and mechanisms, and optimize non-animal approaches that can be used to investigate key events of toxicity. This
paper describes the AOPs and the toolbox of in vitro and in silico models that can be used to assess the key events
leading to toxicity following inhalation exposure. Because the optimal testing strategy will vary depending on
the substance of interest, here we present a decision tree approach to identify an appropriate non-animal in-
tegrated testing strategy that incorporates consideration of a substance's physicochemical properties, relevant
mechanisms of toxicity, and available in silico models and in vitro test methods. This decision tree can facilitate
standardization of the testing approaches. Case study examples are presented to provide a basis for proof-of-
concept testing to illustrate the utility of non-animal approaches to inform hazard identiﬁcation and risk as-
sessment of humans exposed to inhaled substances.
1. Introduction
Acute inhalation toxicity testing is conducted to characterize po-
tential portal-of-entry (POE) eﬀects (those that directly aﬀect the re-
spiratory system) and systemic toxicity hazards of substances that can
be inhaled, including gases, vapors, and liquid (mist) or solid (dust)
aerosols. Both the decision to conduct acute inhalation toxicity testing
and the design of appropriate test systems are informed by an evalua-
tion of a substance's physicochemical properties and other available
information, which will indicate whether inhalation is a likely route of
human exposure and the potential target tissues. Data from acute in-
halation toxicity tests may be used to identify intrinsic hazard proper-
ties of chemicals or end-use products, hazard classiﬁcation and label-
ling, or to inform risk management decisions. Depending on the
approach used, these data may also help elucidate the mechanism
through which a chemical causes toxicity or to select exposure levels for
subsequent subacute and subchronic inhalation tests. Other applica-
tions of acute inhalation toxicity data include development of emer-
gency response guidance levels to inform evacuation or re-entry deci-
sions, setting short-term occupational exposure levels, and informing
operational decisions of military personal facing chemical warfare
threats (Jarabek, 1995a; US EPA, 2009).
Acute inhalation toxicity is deﬁned according to the Organisation
for Economic Co-operation and Development (OECD) as the totality of
adverse eﬀects caused by a test substance following a single, unin-
terrupted exposure over a period of< 24 h (OECD, 2009a). Acute in-
halation toxicity data have historically been generated by exposing
animals to single or multiple inhaled concentrations of a substance in a
short period of time (≤ 24, usually 4–6 h) and assessing the adverse
eﬀects. OECD and other authorities have issued various test guidelines
describing methods to assess inhalation toxicity (US EPA, 1998; 40 CFR
799.9130, 2002; OECD, 2009b; OECD, 2009c; OECD, 2017b). OECD
Test Guideline (TG) 403 (OECD, 2009b) and OECD TG 436 (OECD,
2009c) consider lethality as the primary endpoint, whereas evident
toxicity is the primary endpoint in OECD TG 433 (OECD, 2017b). For
these tests, acute inhalation toxicity may be expressed as a point esti-
mate of the median lethal concentration (LC50; the concentration that
would be expected to cause death in 50% of animals during a 14-day
observation period) (US EPA, 1998; OECD, 2009b); a probit analysis of
exposure-response data based on multiple concentrations and exposure
durations (concentration x time; CxT) (OECD, 2009b); a benchmark
dose analysis (Vincent, 1995; Kulkarni et al., 2011); or a hazard-based
classiﬁcation into categories based on exposure to predetermined ﬁxed
concentrations (OECD, 2009c; OECD, 2017b). LC50 data generated from
these tests are used to categorize and rank test substances based on
lethality, often with little or no elucidation of the site or underlying
mechanism of toxicity. Other acute assessment derivations currently
based on in vivo data consider exposure durations spanning a range
from 10min to 24 h, designate various non-lethal severity categories,
and consider clinical measures or endpoints (e.g., developmental, re-
productive) in addition to LC50 values (Vincent, 1995; OECD, 2016b;
National Research Council, 2017; Hofmann et al., 2018). Developing
non-animal approaches that leverage pathway-based mechanistic
information will not only provide a predictive tool for establishing
potential hazard, but will likely provide more information to the risk
assessor than an LC50 or other in vivo observations.
Extrapolating animal data to predict human health consequences
presents numerous challenges due to physiological, anatomical, and
metabolic diﬀerences across species (e.g. dissimilar airway dichotomies,
types and composition of cells, diﬀerent bio-transforming enzymes, and
physiological variations in breathing patterns and metabolic rates)
(BéruBé, 2013). Data generated in these acute toxicity studies may not
be appropriate or suﬃcient to predict and manage potential adverse
eﬀects in humans (Zbinden and Flury-Roversi, 1981; Balls, 1991;
Chapman et al., 2010; Seidle et al., 2010). As various adverse outcome
pathways (AOPs) following inhalation exposures are elucidated, the
opportunity arises to develop human cell-based in vitro and in silico
approaches to evaluate endpoints relevant to those AOPs. An AOP is a
conceptual framework that organizes existing mechanistic evidence by
connecting—via key event relationships—a deﬁned molecular initiating
event (MIE) on the cellular or subcellular level to subsequently occur-
ring key events (KEs) at the tissue and organ levels that lead to an
adverse outcome at the organism or population level (Villeneuve et al.,
2014b; Villeneuve et al., 2014a). AOPs describe a series of essential,
measurable events culminating in toxicity, and can be useful in deli-
neating endpoints that can be assessed in vitro. These AOP-motivated in
vitro approaches can then be used to inform interspecies extrapolation,
assess target organ eﬀects, and support a better understanding of how
speciﬁc substances cause toxicity in humans (i.e., providing mechanistic
insight that goes beyond what can be gleaned from an LC50 value).
While these approaches are yet to be accepted by global regulatory
agencies, they represent a promising and emerging area of research.
The implementation of alternative approaches for the assessment of
acute inhalation toxicity was the focus of a 2016 workshop co-orga-
nized by the PETA International Science Consortium Ltd. and the U.S.
National Toxicology Program (NTP) Interagency Center for the
Evaluation of Alternative Toxicological Methods (NICEATM)
(Clippinger et al., 2018). This workshop was attended by government
agencies, industry, academics, and non-governmental organisations
interested in developing approaches that can replace or reduce the use
of animals for acute inhalation toxicity testing. Experts in attendance at
the workshop were tasked with developing a strategy to establish
conﬁdence in these approaches.
Working groups were formed to fulﬁll each of the workshop re-
commendations. One of these recommendations was to publish the
current paper, a state-of-the-science review to:
1) Detail the mechanisms of acute inhalation toxicity of inhaled sub-
stances (gases, vapors, and dust/mist aerosols), and deﬁne relevant
AOPs that could be used to inform the appropriate integrated testing
and assessment approach;
2) discuss the inﬂuence of physicochemical properties (e.g., pH, low
volatility, gas category, and particle size) on the relevance of in-
halation as a route of exposure or on the ability to generate a test
atmosphere;
3) summarize factors inﬂuencing dosimetry as well as the potential for
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POE eﬀects, including physicochemical characteristics, airway ar-
chitecture, ventilation rate, blood ﬂow, and metabolism;
4) catalog the currently available and emerging non-animal (non-
testing and in vitro testing) approaches relevant to these mechanisms
and deﬁne their usefulness and limitations; and
5) using information from the points above, develop a decision tree
and discuss the steps necessary to implement an integrated approach
to testing and assessment(s) (IATA) that will reduce and replace the
use of animals for acute inhalation toxicity testing
The following sections discuss each of these areas, concluding with
a deﬁnition of activities needed to develop IATAs that will succeed in
replacing animal use for assessing inhalation hazards. Such IATAs are
likely to include a combination of any existing evidence (including
epidemiological and toxicological data), exposure information, physi-
cochemical properties of the test material, non-testing approaches (e.g.,
QSARs, read-across, or computational dosimetry models), and in vitro
testing. The optimal approach will likely continue to evolve as more
data and approaches become available, and as our understanding of the
mechanisms of toxicity advances. Because the LC50 is commonly used as
a metric for regulatory needs (e.g., hazard classiﬁcation), there is an
interest in developing non-animal approaches to predict either point
estimates of LC50 or ranges of LC50 values that could be used for hazard
classiﬁcation. Ultimately, however, these non-animal approaches may
provide mechanistic information on how inhaled substances cause
systemic toxicity or POE eﬀects in humans, thereby providing a better
characterization of their potential hazards than existing in vivo
methods. While this paper focuses on acute inhalation toxicity testing,
many of the cell systems and concepts discussed herein could be
adapted and applied to designing longer-term repeat dose inhalation
studies.
2. Biological pathways of inhalation toxicity
Designing an appropriate IATA for inhalation toxicity requires
considering both dosimetry and the underlying biological processes that
link exposure to non-lethal and lethal outcomes. Key to development of
such an IATA is the identiﬁcation and evaluation of relevant AOPs. A
framework that parallels AOPs and applies to exposure science is the
aggregate exposure pathway (AEP), which organizes exposure data and
predictions to link the introduction of a stressor from sources, transport,
and transformation through environmental media, patterns of external
exposure, and biokinetic processes leading to target site exposures
(TSEs). The TSE is the point of integration between the AEP and AOP,
representing a specialized KE characterizing the concentration at the
biological location of the MIE in an AOP (Cheng and Moss, 1995), and a
critical consideration for dose-response analysis in risk assessment. The
TSE is measured at the level of organisation corresponding to a deﬁned
protection goal; for example, the TSE could be a cellular concentration
or an air concentration, depending on the assessment objective. The
AEP framework allows for integration of exposure science with AOPs
and dose-response data, linking exposure and hazard. Together, AEPs
and AOPs create a ﬂexible framework that enables risk-based, hazard-
based, or exposure-based decision making (Fig. 1) (Teeguarden et al.,
2016). Here we focus on the biological (anatomical and physiological)
factors involved in describing the TSE and KEs of an AOP for an inhaled
agent.
Following inhalation exposure, toxicity may be induced via multiple
mechanisms. Methods that focus solely on the generation of LC50 values
are limited in their ability to generate data that support a better un-
derstanding of these mechanisms (Hamm et al., 2017). However, pro-
gress has been made in recent years to use information from mechan-
istic approaches to develop AOPs. AOPs provide a framework to better
understand the mechanisms that lead to adverse outcomes (local POE
toxicity and systemic toxicity) following inhalation exposures, and
substantial work is underway to further develop AOPs related to in-
halation exposure (Table 1). Table 1 shows speciﬁc AOPs with potential
relevance to acute inhalation toxicity based on the general KEs illu-
strated in Fig. 2 (https://aopwiki.org/aops; accessed 22 January 2018).
These AOPs describe adverse outcomes (acute or otherwise) that are
likely to occur in the respiratory tract, or encompass MIEs, KEs, or
adverse outcomes that are relevant to the mechanisms in Fig. 2. Any
stressor that evokes the MIE in question may potentially lead to the
adverse outcome in humans and one substance may perturb multiple
AOPs (Allen et al., 2014). Speciﬁc adverse outcomes may take diﬀerent
timeframes to be expressed, and also depend on the exposure con-
centration, frequency, and duration.
AOPs can be used to help identify suitable non-animal tests to assess
speciﬁc KEs. As additional in vitro data are collected, they can be used to
further develop AOPs (Ankley et al., 2010; Tollefsen et al., 2014). The
iterative nature of the AOP development process means that, as
knowledge gaps are ﬁlled, pathways and testing strategies can be
continually reﬁned, guiding the in vitro and non-testing approaches
required to support regulatory decision-making (Tollefsen et al., 2014).
Thus, AOP-informed IATA development can drive the evolution of in
vitro or non-testing approaches that contribute to a mechanistic un-
derstanding of acute inhalation toxicity and improved hazard assess-
ment for potential human exposure scenarios. Ideally, the integration of
all information will also lead to the development of quantitative AOPs
that can be used for dose-response analyses (Wittwehr et al., 2017), and
iteratively, inform reﬁnements of the next generation of mechanistic
IATAs.
Fig. 1. Integration of exposure information into an aggregate exposure pathway:adverse outcome pathway (AEP:AOP) framework. Key events (KE) in the AOP are
indicated by the pink-colored boxes. The arrows between the environmental air contaminant source to the target site exposure (TSE) denote key exposure states (e.g.,
in diﬀerent media) representing a measurable change in a chemical state and concentration that describes the movement of a chemical from a source to the TSE in the
AEP. The TSE in the respiratory tract that corresponds to the MIE (e.g., dose to a given region or cell type in the portal of entry or delivered to a systemic target tissue)
links the AEP and AOP frameworks for inhaled agents. Toxicokinetics (TK) refers to the processes of absorption, distribution, metabolism, and elimination (ADME) of
a toxicant while toxicodynamics (TD) refers to the processes of a toxicant within an organism at the organ, tissue, cellular, and molecular level (Faustman and
Omenn, 2013).
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Table 1
Key events with potential relevance to toxicity following acute or longer-term inhalation exposures and associated AOPs (hyperlinks direct to speciﬁc AOP in the
AOPWiki).
MIE/key events Example stressor Adverse outcome Reference
- Acetylcholinesterase inhibition
- Accumulation of acetylcholine in synapses
- Increased atrioventricular block and bradycardia
- Increased respiratory distress
- Induction of ataxia, paralysis, or hyperactivity
Organophosphorous compounds Acute mortality (AOP 16) (Russom et al., 2014)
- Axonal sodium channel inhibition
- Prolonged depolarization of neuronal membrane
- Neurotransmitter release
- Muscle contraction
- Induction of ataxia, paralysis, or hyperactivity
Volatile anaesthetics Acute mortality (AOP 96) N/A
- Cell injury
- Narcosis (membrane disruption)
- Decompartmentalization
- Direct mitochondrial inhibition
Cytotoxicity
(AOP 205)
(Vinken and Blaauboer, 2017)
- Narcosis (membrane disruption)
- Decreased cell respiration and metabolism
- Decreased respiration
Volatile organic compounds (VOC)
and solvents
Respiratory failure (AOP 35) (Perkins et al., 2015)
- Oxidative Stress
- ILC2 modulation
Respiratory epithelial remodeling
(AOP 239)
(Jarabek and Harkema, in
preparation)
- EGFR activation (phosphorylation)
- Transdiﬀerentiation of ciliated epithelial cells
- Goblet cell metaplasia
- Hyperplasia of goblet cells
- Proliferation of goblet cells
- Apoptosis of ciliated epithelial cells
- Transcription factor (SP1) modulation
- Increased mucus production
Cigarette smoke Decreased lung function
(AOP 148)
(Luettich et al., 2017)
- Oxidative stress-mediated perturbation of endothelial
nitric oxide bioavailability
- Glutathione oxidation
- S-Glutathionylation, eNOS
- Decrease in GTPCH-1
- Decrease in tetrahydrobiopterin
- Uncoupling of eNOS
- Depletion of nitric oxide
- Impaired vasodilation
- Increase in vascular resistance
- Decrease in Akt/eNOS activity
Cigarette smoke Hypertension
(AOP 149)
(Lowe et al., 2017)
- Glucocorticoid receptor activation
- Inhibition of NF-ĸB
- Suppression of inﬂammatory cytokines
- Decreased lymphocytes
- Induction on IĸB
- Suppression of the immune system
Corticosteroids Increased disease susceptibility (AOP 14) N/A
- Inhibition of vitamin K epoxide reductase (inhibition of
vitamin K cycle)
- Depletion of functional clotting factors
- Failure to form clot
- Prevention of vascular repair
Anticoagulant rodenticide Coagulopathy and haemorrhage
(AOP 187)
(Rattner et al., 2014)
- DNA alkylation
- Failure of DNA repair
- Mutation
Cyclophosphamide Cancer (AOP 139) N/A
- Protein alkylation
- Cell injury/death
- Activation and recruitment of Kupﬀer cells
- Upregulation of TGFbeta1 expression
- Activation of stellate cells
- Collagen accumulation
2-Iodoacetamide Liver ﬁbrosis
(AOP 38)
(Horvat et al., 2017)
- Organic anion transporter (OAT1) inhibition
- Increase in uric acid concentration in the blood
- Renal proximal tubular necrosis
- Increased blood potassium concentration
- Increased tophi (urate) deposition
- Increased occurrence of cardiac arrhythmia
- Increased oxidative stress
NSAIDs Renal failure and mortality
(AOP 138)
N/A
- Nav1.1 channel inhibition
- Decreased sodium conductance
- Reduced swimming speed and feeding in ﬁsh, leading to
increased predation
Volatile anaesthetics Reduced survival (AOP 95) (Fay et al., 2017)
- Chronic cytotoxicity of the serous membrane
- Persistent cytotoxicity
- Increased inﬂammation
- Increased oxidative stress
- Increased secretion of local growth factors
- Increased cell proliferation
Asbestos Mesothelioma (AOP 171) N/A
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3. Developing an IATA for inhalation testing
Integrated approaches to testing and assessment (IATA) are prag-
matic, science-based approaches for chemical hazard or risk char-
acterization that rely on an integrated analysis of existing information
in a weight of evidence assessment coupled with the generation of new
information using testing strategies (OECD, 2016c). IATA follow an
iterative approach to answer a deﬁned question in a speciﬁc regulatory
context, taking into account the acceptable level of uncertainty asso-
ciated with the decision context, and thus aﬀord the ﬂexibility required
to address the various applications identiﬁed herein for inhalation
testing and translation. Development of successful IATA has been de-
monstrated to evaluate both skin irritation or sensitization and eye ir-
ritation (OECD, 2014; OECD, 2016b; OECD, 2017a) but there is a need
for a systematic framework to characterize the individual biological and
toxicological relevance of in vitro methods for predicting toxicological
endpoints from inhalation exposures, notably those challenges are in-
herent in assessing toxicity to the respiratory tract.
The respiratory tract is composed of> 40 types of cells that are
localized to speciﬁc regions based on their function (International
Commission on Radiological Protection (ICRP), 1994; Parent, 2015).
For example, the upper respiratory tract includes the respiratory,
transitional, and olfactory epithelium; including sustentacular cells,
ciliated cells, and basal, goblet, serous, and brush cells. The alveolar
region is comprised of alveolar type I and type II (surfactant-producing)
cells, serous cells, and Club cells (Crapo et al., 1982; Crapo et al., 1983;
Parent, 2015). Immune cells (e.g., dendritic cells and macrophages)
exist in diﬀerent locations throughout all respiratory regions (Holt,
2005; Brain, 2011).. These diﬀerences in populations of cell types as the
airways move from being conducting to respiratory in function (e.g. the
replacement of goblet with Club cells; which begins in the bronchioles),
make studying the respiratory tract a unique challenge, and the choice
of a representative test system is paramount to obtaining relevant re-
sults. Creating one in vitro test system containing all of these cell types is
currently not technically feasible. However, systems containing cells
critical to a given pathogenesis (alone or in co-culture) could be useful
to predict the eﬀects of inhaled substances in speciﬁc regions of the
respiratory tract.
The complexity of the respiratory tract underscores the importance
of using an AOP framework as a mechanistic scaﬀold to aid in the de-
sign of intelligent in vitro and in silico testing approaches to inhalation
exposures. By applying AOP-directed knowledge and understanding,
the following components are likely to contribute, combined with other
tools and methods, to the development of deﬁned approaches (OECD,
2016a) and IATA on guidance for testing and interpretation of inhala-
tion exposures.
a. Physicochemical property information
Development of an IATA starts with problem formulation, an ap-
proach to toxicological risk assessment that links the exposure scenario
of interest to a substance's potential adverse health outcomes in hu-
mans. Problem formulation considers factors such as the purpose of the
assessment, physicochemical properties of the test substance and its
potential dosimetry or ADME processes, likely exposure concentration
and route of exposure, exposed populations, exposure scenario (e.g.,
consumer versus occupational exposure), existing information, which
methods to use for the generation of new data, and the relevant end-
points to assess (US EPA, 2014; Borgert et al., 2015; National Research
Council, 2017).
If exposure to a test substance is either known to be minimal or
predicted to be minimal based on physiochemical property information,
certain regulatory requirements for testing could be reconsidered. For
example, a large particle size (aerodynamic diameter > 100 μm), low
Fig. 2. Selected key events and adverse outcomes that may occur systemically or in the respiratory tract as the portal of entry following acute exposures to an inhaled
material. The TSE is a function of dosimetry including absorption, distribution, elimination and metabolism (ADME) processes that dictate disposition of the parent
chemical or its metabolite(s). Chronic lung eﬀects may occur as a result of acute toxicity that does not cause death or with repeated acute exposures notably when
either the chemical or its damage persists; exposure concentration, frequency, and duration also impact the trajectories of diﬀerent pathways. Tissue remodeling
would not be evident after a single acute exposure, and protective cellular eﬀects that could mitigate the listed adverse responses are not listed here. Additionally,
while respiratory sensitization may occur following repeated acute exposure to an inhaled substance, this endpoint is not included as it is not generally considered in
the current acute systemic toxicity animal tests.
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volatility, and high viscosity would suggest that the substance is not
inhalable by humans without some form of physical manipulation (e.g.,
low volatility substances sprayed into the air). Thus, this information is
important to consider before generating new data and can provide
context for the interpretation and translation of existing information for
both the substance of interest and analogous substances. However,
caution must be used with this approach as there may be situations
where a chemical not expected to be inhaled is incorporated into a
product that is delivered as an aerosol or some other manner that in-
creases inhalability.
Once access to the respiratory tract is established as a likely route of
inhalation exposure, physicochemical property information can also
then be used to determine whether it is technically feasible to test a
substance and to inform a testing strategy. For instance, the vapor
pressure of a gas or the partial pressure of the components in a mixture
can provide an indication of its volatility, informing whether it will be
possible to generate a test atmosphere. Test material density and size
distribution are determinants of aerosol physics that provide informa-
tion on the technical feasibility of testing.
Test material density and size distribution also determine the local
dosimetry of a substance in the airways or to remote systemic sites and
thus help inform considerations for characterizing the TSE and requisite
features for design of an in vitro test system (Clippinger et al., 2018).
Particle size aﬀects inhalability and how deeply into the respiratory
tract a substance would penetrate (Heyder et al., 1986; Patton and
Byron, 2007), which will in turn determine whether an in vitro model of
the upper and/or lower respiratory tract is more appropriate. For ex-
ample, small particles, such as nanomaterials, are able to deposit in all
regions of the respiratory tract, including penetrating deeply into the
lung to the alveoli. Alveolar macrophages have been shown to be im-
portant in clearing the alveoli from particles; therefore, alveolar mac-
rophages may present a useful test system to assess the eﬀects of na-
nomaterials and other small particles (Clippinger et al., 2016; Wiemann
et al., 2016). In addition, nanoparticles have been demonstrated to
deposit in the nasal region and subsequently translocate to the brain
(Oberdorster et al., 2004; Oberdorster et al., 2009).
Other physicochemical properties of a substance (e.g., chemical re-
activity, water, and lipid solubility) will additionally aﬀect whether its
potential toxicity will predominantly manifest as local eﬀects in the
respiratory tract or systemic eﬀects and thus aid in determining the
most relevant in vitro test system (Kriebel et al., 2007; Grimm et al.,
2016; Stanton and Kruszewski, 2016). For example, a strong acid or
base or a substance that contains structural features indicative of
electrophilicity or reactivity in tissues (such as epoxides or α/β un-
saturated aldehydes) may have the potential to cause local POE eﬀects
such as respiratory irritation or corrosion. In particular, non-lung cell
systems will be needed to assess substances with properties that make
them likely to be absorbed through the lung tissue and cause organ-
speciﬁc toxicity in locations other than the respiratory tract (e.g., heart,
liver, or nervous system). Consideration must also be given to meta-
bolites that may possess diﬀerent physical properties than the parent
compound, potentially altering distribution and other target organ ex-
posures. Human lung samples and three-dimensional reconstructed
human tissues models have been characterized for their expression of
key metabolic enzymes (Castell et al., 2005; Bernauer et al., 2006;
Willoughby, 2015).
b. Non-testing approaches
Several diﬀerent types of non-testing approaches can help predict
the toxicity of substances after inhalation exposures and can be used in
a “ﬁt for purpose” fashion to address various assessment needs that
span from prioritization, hazard identiﬁcation, quantitative risk as-
sessment, and national exposure standard setting (Bell et al., 2018). For
the purposes of this manuscript, the phrase “non-testing approaches”
describes (1) empirical grouping approaches; (2) quantitative structure-
activity relationship (QSAR) analyses; (3) expert systems; and (4) me-
chanistic computational dosimetry models. These approaches, to
varying degrees, are based on the underlying principle that similar
substances are expected to exhibit similar biological activities.
i. Computational models based on historical data or chemical struc-
ture
Grouping approaches, such as read-across (i.e., applying data from
one substance(s) to predict the same property or eﬀect for a structurally
‘similar’ substance), use data mining approaches to ﬁll data gaps and
delineate chemical categories. Grouping—which encompasses category
and analog approaches and data gap-ﬁlling techniques—generally uses
a structure-based approach to deﬁne categories of substances; these
categories can then be used to generate hypotheses about toxicity and
mechanisms of toxicity of untested chemicals.
QSARs are theoretical models that can be used to predict the phy-
sicochemical, biological, and environmental fate properties of sub-
stances based on a knowledge of their chemical structure in a qualita-
tive or quantitative manner (ECHA, 2008). Guiding principles exist to
facilitate QSAR use for regulatory purposes. OECD has described ﬁve
principles that collectively characterize the scientiﬁc validity of a spe-
ciﬁc QSAR (OECD, 2004; OECD, 2007; Patlewicz et al., 2016). One
principle describes the importance of deﬁning an applicability domain
for the QSAR model itself so that the adequacy of the prediction for a
given substance can be assessed. The applicability domain is extracted
from the training set of chemicals used to derive the QSAR model.
Expert systems are software tools that use QSARs to predict toxicity
based on chemical structure; expert systems are usually categorized as
knowledge-based, statistics-based, or hybrids (Patlewicz et al., 2007;
Worth et al., 2007).
The availability of non-testing approaches to predict toxicity after
acute inhalation exposures is limited. The commercial expert system
TOPKAT is a structure-based global QSAR model that speciﬁcally aims
to predict an LC50 value that would be generated in a rat four-hour
inhalation test (https://omictools.com/toxicity-prediction-by-
komputer-assisted-technology-tool). Because the model, data, and
training set used are proprietary, and it has not been described in the
peer-reviewed literature, a deﬁnitive evaluation of its utility remains a
challenge. Local QSARs for prediction of inhalation toxicity include one
developed by Veith et al., which uses log vapor pressure as a predictor
of LC50 (expressed as the log molar equivalent) for volatile neutral or-
ganic substances assumed to cause toxicity via narcosis (Veith et al.,
2009); however, the applicability domain does not extend coverage to
other physicochemical properties or endpoints.
Information submitted under the European Union Registration,
Evaluation, Authorisation and Restriction of Chemicals (REACH) is
used in toxicity prediction tools such as OECD's QSAR Toolbox (https://
www.qsartoolbox.org/), and the OECD's eChemPortal (www.
echemportal.org) provides information on chemical properties, ex-
posure, and toxicity. These data could be further exploited to facilitate
development of new QSAR models for predicting inhalation toxicity. In
fact, the REACHAcross™ software (www.ulreachacross.com/REACH)
was developed using these REACH data. MultiCASE has also recently
released a QSAR model to predict acute inhalation toxicity.
Other sources of inhalation data exist in the U.S. Centers for Disease
Control's Registry of Toxic Eﬀects of Chemical Substances (www.cdc.
gov/niosh/rtecs/default.html); this data set is available under license
from Accelrys (www.accelrys.com) and value-added resellers such as
Leadscope Inc. (www.leadscope.com). The OECD QSAR Toolbox also
encodes proﬁling tools called SAR rule bases that help group substances
into toxicological categories on the basis of a presumed mode of action
(e.g., unspeciﬁc reactivity, polar narcosis, baseline narcosis, or receptor-
mediated toxicity) and structural similarity. This information is key to
identifying relevant source analogs for read-across predictions and de-
termining whether additional in vitro testing should be conducted.
A.J. Clippinger et al. Toxicology in Vitro 52 (2018) 131–145
136
Additional work is needed to develop and optimize QSARs and non-
testing approaches for predicting the potential toxicity of inhaled ma-
terials.
ii. Mechanistic computational dosimetry models
In general, dosimetry involves determining the amount, uptake rate,
and distribution of a substance in the body and various models can be
used to predict these factors (Kuempel et al., 2015). Disposition of in-
haled agents in the respiratory tract encompasses the processes of initial
inhalability, airﬂow convection and diﬀusion, and ADME processes.
The major determinants of disposition, which include the physico-
chemical properties of an inhaled agent and the anatomy and phy-
siology of the respiratory tract, determine the initial deposition and
subsequent disposition within the respiratory tract, distribution to other
systemic tissues, and ultimately the toxic eﬀect. These determinants
have been described and previously reviewed (Clippinger et al., 2018).
Studies that mimic realistic exposure conditions (such as exposure
concentration, duration, and in the case of aerosols, particle density,
size, and distribution) will be most likely to generate results that are
predictive of human outcomes. Development of risk assessments require
dose-response information with a range of doses relevant to human
exposure.
There are two general categories for inhalation dosimetry: aerosols
(including ﬁbers and nanomaterials) and gases (including vapors);
within gases there are three major categories for dosimetry model se-
lection (gas Category 1, 2, and 3; see Table 5 in (Clippinger et al.,
2018)). Consideration of physicochemical properties according to these
gas categories will be essential to the selection of the test system and
the evaluation and extrapolation of the eﬀects to a given target human
equivalent. Diﬀerent mathematical models can be applied to the three
diﬀerent categories of inhaled agents and span a range from default
algorithms to sophisticated computational models with detailed struc-
tures to address all anatomical, physiological, and physiochemical de-
terminants and their interactions, as previously summarized
(Clippinger et al., 2018). The choice of model structure depends on the
available data and the dose metric desired, for example, the regional
uptake or a localized dose to a speciﬁc cell type (US EPA, 1994;
Jarabek, 1995b; Kuempel et al., 2015).
An example of a sophisticated model routinely used to estimate
particle dose in vivo (humans and animals) is the Multiple-Path Particle
Dosimetry (MPPD) model (www.ara.com). The MPPD model can be
used for interspecies extrapolation and to describe the inhaled dose of
various exposure scenarios. Tools to help set and translate in vitro doses
include the in vitro sedimentation, diﬀusion, and dosimetry model,
which describes the dose delivered to the cell (Hinderliter et al., 2010),
and its extension, the in vitro sedimentation, diﬀusion, dissolution, and
dosimetry model or ISD3 model, which addresses soluble particoki-
netics in vitro (Thomas et al., 2018). Models for reactive gases include
computational ﬂuid dynamics (CFD) models and typical-path mass
transfer descriptions or hybrid CFD-PBPK models (Kimbell et al., 2001;
Overton et al., 2001; Schroeter et al., 2006; Schroeter et al., 2010;
Corley et al., 2012; Kolanjiyil and Kleinstreuer, 2017). Models for so-
lids, liquids, and gases with pulmonary absorption linked to systemic
distribution and clearance include physiologically-based pharmacoki-
netic (PBPK) models (Backman et al., 2014; Borghardt et al., 2015;
Backman et al., 2018). Development of approaches linking dosimetry
models describing in vivo dose metrics associated with diﬀerent ex-
posure scenarios for particles or gases with in vitro systems will help
translation and application of in vitro data.
c. In vitro and ex vivo testing methods
In vitro to in vivo extrapolation (IVIVE) methods are a key resource
for correlating bioactive chemical concentrations in in vitro assays to
plasma and tissue dose levels that lead to adverse eﬀects in vivo. An
accurate estimate of the toxicological eﬀects of a substance depends on
the input factors used for the IVIVE calculation (i.e., dosimetry and
ADME). To perform an accurate IVIVE, the cellular concentration is a
more reliable dose metric to serve as the basis for translation and
alignment of exposure and test systems compared to the nominal ex-
posure concentration (Hinds, 1999; National Research Council, 2017).
In silico fate models to describe free in vitro concentration have been
developed (Kramer, 2010; Armitage et al., 2014; Comenges et al., 2017;
Fischer et al., 2017). These models describe the in vitro test system as a
set of mathematical equations and simulate the chemical partitioning
between proteins, plastics, and lipids in the cell culture medium and
within the cell. Models currently include a lung cell line (Zaldívar et al.,
2012) and the 3 T3 Balb/c ﬁbroblast cell line (Kramer et al., 2012;
Comenges et al., 2017; Proença et al., 2017).
ii. In vitro models of the respiratory tract
In vitro cellular systems diﬀer not only with respect to the types of
cells included, but also the format in which they are grown (e.g., sub-
merged or grown at the air-liquid interface), which inﬂuences im-
portant transport and transformation mechanisms. Each system has its
advantages and limitations and the choice of which system to use will
depend on the speciﬁc purpose of the testing. While submerged
monolayer cultures have been used extensively to study basic human
airway biology and to elucidate mechanisms of toxicity, co-culture
systems comprised of epithelial and other cell types (e.g., lung residence
immune cells) and structured to incorporate an air-liquid interface can
be used to more closely recapitulate physiological conditions and study
cell-cell interactions. Studies showed that functional and phenotypic
characteristics, such as beating cilia and active mucus secretion, can be
successfully reproduced in an air-liquid interface system. Systems in-
cluding commercially available three-dimensional reconstructed tissue
models and biomimetic models such as the breathing human lung-on-a-
chip can be exposed to a test substance at the air-liquid interface. In
addition to considering the biological system for evaluation, the
method for exposing the test chemical is also important; for example,
whether a vapor or aerosol will be generated to expose cells, or whether
a liquid will be applied directly to a tissue or cell culture. The properties
of the test chemical will impact the exposure method decision.
The use of co-culturing to create a more in vivo-like situation can
take three forms: 1) the addition of multiple cell types within or closely
related to the organ in question; 2) the inclusion of immune cells; or 3)
the use of cells from other organs to generate a multi-organ-based ap-
proach (Prytherch and BéruBé, 2014). The ﬁrst scenario might involve
the co-culture of bronchial or alveolar cells, ﬁbroblasts, and endothelial
cells. An immune cell type(s) may be added to the airway epithelium
alone or to a more complex co-culture model of the epithelium. Multi-
organ-based co-cultures attempt to recreate the potential downstream
fate of inhalable compounds. For instance, many potential therapeutics
fail due to cardiotoxic or hepatotoxic eﬀects, making the use of a
connected system of respiratory, liver, and/or heart cells attractive.
Careful characterization of the mechanistic competencies (e.g., anti-
oxidant capacities, metabolic proﬁles) as well as the structure, barrier
properties, and spatial arrangement of the cells in the test system is
important when selecting the system. Human primary cells (e.g., human
bronchial epithelial (HBE) cells or small airway epithelial cells (SAEC))
or human-derived cell lines (e.g., BEAS-2B, Calu-3, A549, or NCI-H292)
have been widely used to better understand how a substance is likely to
aﬀect humans. In particular, there is much interest in the use of primary
human cells due to their biologic-relevance, such as the ability to
maintain expression of important markers and functions seen in vivo.
iii. Ex vivo models of the respiratory tract
Ex vivo human precision-cut lung slices (PCLS) are relevant to study
airway biology and the adverse eﬀects of inhaled toxicants. Human
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PCLS are created from organs donated, but not used, or from surgically
removed tissue. As with reconstructed human airway models generated
from donor cells, either healthy or diseased tissue may be used in
toxicological studies, depending on the goal of the study. Years of
published research has demonstrated PCLS metabolic competence
(Vickers et al., 1997; De Kanter et al., 2002a; de Kanter et al., 2002b)
and sensitivity to known pulmonary toxicants (Fisher et al., 1994;
Switalla et al., 2010). While this system lacks recruited immune cells,
PCLS contain resident immune cells that allow for immune respon-
siveness (Sewald and Braun, 2013; Lauenstein et al., 2014) (Hess et al.,
2016). Several characteristics unique to PCLS include native archi-
tecture of the lower respiratory tract and a full complement of cell types
(including macrophages and dendritic cells) in the tissue at the time of
slice creation. PCLS can be particularly useful for applications that re-
quire maintenance of cultures for several weeks (Morin et al., 2013;
Westra et al., 2013). The small size of PCLS conﬁnes slice creation to
the periphery of the lung and includes the respiratory parenchyma
(alveolar space) and small airways, the latter allowing for functional
studies involving airway contractility.
iv. Selection of in vitro / ex vivo test systems
Reviews of exposure generation and characterization (Cheng and
Moss, 1995; Kennedy et al., 1995; Moss and Cheng, 1995; Vincent,
1995; Wong, 1995; Hinds, 1999; Kulkarni et al., 2011; Polk et al., 2016)
and in vitro and ex vivo systems (BéruBé et al., 2009; BéruBé et al., 2010;
Gordon et al., 2015; National Academies of Sciences and Medicine,
2015; Wiemann et al., 2016) that can be used to assess the toxicity of
inhaled substances were published previously. As for in vivo exposure
systems, generation and characterization of exposures both in the
system and at the cell interface, analytical considerations such as ap-
propriate methods for detection of a speciﬁc chemical, and determi-
nation of proper operating conditions (e.g., temperature, relative hu-
midity, ﬂow rates) are critical to ensure consistent results from in vitro
systems. Additionally, the diﬀerences in culture systems (e.g., three-
dimensional or monolayer) and cell types (e.g., metabolic competencies
and anti-oxidant capacities) must be considered when selecting a test
system (Sauer et al., 2013; Zavala et al., 2016).
Supplementary Table 1 provides an updated summary of the cell
types, biomarkers, and test substances that have been used in the
published literature. While the table does not represent an exhaustive
list of every cell type that could be used, the existing information il-
lustrates current capabilities and may help inform selection of a cell-
based system to test a new substance.
Selection of an in vitro system will depend on the substance being
tested and the objective of the study (e.g., prioritization/screening or
hazard classiﬁcation versus quantitative risk assessment). In general,
analysis of the substance's properties can be used to predict whether it
is likely to be reactive; if so, a preliminary screen for overt toxicity
could be conducted in a simpler monoculture test system. While a re-
spiratory cell model may be critical to assess respiratory-cell-speciﬁc
mechanisms, it is likely that other (non-respiratory tract) cell types may
be suﬃcient to assess general cytotoxicity (Sauer et al., 2013). Use of a
monoculture test system comprised of mammalian epithelial cells may
also be suﬃcient if the primary purpose of testing is to rank the toxicity
of several compounds to determine which to prioritize for further
testing. A monoculture system could also be used to examine acute
endpoints, but a model with longer viability would be needed if the goal
of the study is to examine repeated exposures or longer-term endpoints.
The appropriate cell system can be selected after determining
Table 2
Considerations and tools useful to the development of an IATA to assess eﬀects after inhalation exposures.
Exposure use case • Problem formulation is ﬁrst step of targeted testing or assessment approaches. Obtaining human exposure data under real-world conditions (e.g.,
monitoring for air concentrations and particle size distributions in the human breathing zone in a ﬁeld study) may provide more robust evidence of
human exposure potential versus laboratory data or default assumptions (National Research Council, 2009).
• Population demographics (e.g., age, sex, and race)
• Exposure regimen (e.g., frequency)
• Exposure duration
• Inhaled agent (e.g., particle or gas)
• Concentration (mg/m3)
Existing information • Human e.g., case reports from accidental or intentional exposures, studies of bronchoalveolar lavage (BAL) ﬂuid.
• In vivo toxicity
• In vitro toxicity
• Information related to the likelihood of exposure
• Information on the intended use or target of the chemical
Physicochemical properties • Physical form e.g., gas, liquid, or solid
• Viscosity
• Volatility e.g., what is the substance's vapor pressure?
• Particle density, size, and distribution e.g., is the substance inhalable or likely to enter the bloodstream?
• Gas category e.g., reactive substances (gas Category 1) or volatile organic compounds (gas Category 3)
• Irritation/corrosivity as predicted by pKa (e.g., is the substance a strong acid or base?)
• Solubility in airway surface liquid, phagolysosomal ﬂuid, or mucus
Chemical properties • Reactivity e.g., is the test substance—parent compound or metabolite—electrophilic or likely to react via one of the reaction mechanistic pathways:
• Hydrolysis• Oxidation• Acylation• Alkylation• Nitrosylation• Michael addition reaction• Schiﬀ base formation
Dosimetry modeling • To predict dose metric in speciﬁc respiratory tract region or delivered to systemic target tissues
Non-testing methods • QSARs, grouping, read-across, and computational dosimetry models
• Threshold of toxicological concern
• For mixtures: theory of additivity
Weight-of-evidence analysis • Review existing information, physicochemical properties, and non-testing methods to decide if additional testing is needed.
In vitro testing • The information in the above rows can be used to inform selection of an in vitro test system(s) to interrogate POE and systemic eﬀects following
inhalation exposures. See Supplementary Table 1 for examples of in vitro systems of interest to assess toxicity following exposure to inhaled
substances.
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whether the inhaled substance is likely to cause local POE eﬀects,
systemic toxicity, or both. If the substance is expected to cause systemic
toxicity, PBPK models or default algorithms to predict systemic dose at
target organ could be used to evaluate the ADME of the chemical in the
body and its toxicity. These models can be combined with data from a
general cytotoxicity assay, such as the 3 T3 neutral red uptake assay
(ECVAM, 2013; Prieto et al., 2013), or data from other in vitro assays.
An understanding of the dosimetry determinants and mechanism of
toxicity or relevant AOP will help identify potential systemic toxicity
sites and therefore, cell types to include in the test system. Conversely,
if a substance is expected to cause local POE eﬀects, such as respiratory
irritation or sensitization, in vitro systems using appropriate respiratory
cell types should be used. For example, an adverse outcome pathway
and testing approaches have been proposed for sensitization of the re-
spiratory tract (Kimber et al., 2014; North et al., 2016; Sullivan et al.,
2017).
Identifying which in vitro endpoints (e.g., apoptosis, barrier in-
tegrity, cytotoxicity, ER stress, inﬂammation, oxidative stress, or
genomic/proteomic endpoints) are most predictive of whether an ad-
verse outcome will manifest in humans is critical. Consideration should
be given to how a perturbation in a human tissue model informs the risk
assessment process. New tools and approaches should be developed and
evaluated considering that many real-world human exposures are
mixtures of multiple substances. There is also a need to analyze data
produced using standardized protocols evaluating various endpoints to
deﬁne the applicability domain of each test system. An example of a
decision process to identify the appropriate test system is provided in
the following section.
4. Decision tree and case studies
Adverse outcomes related to inhalation exposure can be predicted
through the use of IATAs, which may consider existing information,
likely exposure levels, physicochemical properties of the test substance,
dosimetric determinants, mechanistic insights, and data from in silico
and/or in vitro models (Table 2). The IATA will vary depending on the
properties of the substance being tested and the purpose of the study.
4.1. Decision tree
The following decision tree is proposed to help guide consideration
of the exposure parameters and design of an integrated strategy for
inhalation testing (Fig. 3). Because the desired testing strategy varies
depending on various factors, a decision tree that can be used to inform
what testing is most appropriate is important. For example, current
acute inhalation toxicity test guidelines used for calculating an LC50
allow waiving testing when the chemical has certain properties (e.g.,
Fig. 3, steps 3 and 4); characterization of acute toxicity for other risk
assessment applications (i.e., other than determining an LC50) may re-
quire additional considerations. Such considerations include the likely
nature of the acute exposure (e.g., its frequency and duration) and
characteristics of the exposed population (e.g., occupational or en-
vironmental). Careful evaluation of whether the chemical or its damage
will persist is also necessary. Thus, the ﬁrst step of problem formulation
is to evaluate purpose of the assessment (e.g., emergency response), the
target exposure scenario, and characteristics of the inhaled agent. The
target scenario includes parameters that characterize speciﬁc popula-
tion considerations (e.g., occupational, general population, adults, or
children), exposure duration (e.g., hours per day) and exposure regimen
(e.g., number of days per week or a more routine, intermittent pattern
of exposures).
The human equivalent concentration (HEC) for these scenarios is
calculated with diﬀerent models for particles or gases. The general
equation is provided here for interspecies extrapolation with con-
siderations for application to in vitro systems:
HECPOD=PODADJ * DAF.
Fig. 3. Decision tree that can be used to guide consideration of the exposure parameters and design of an integrated strategy for inhalation testing. Results of proof-
of-concept testing based on this decision tree, the AOPs in Table 1, and the considerations in Table 2 can be evaluated to develop guidance on classiﬁcation and other
inhalation toxicity applications. The decision tree does not supplant expert judgement but is intended as conceptual structure to help identify considerations for
experimental design.
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Where:
The HEC is the human equivalent concentration corresponding to
the POD of the experimental system (e.g., either the in vivo study for
interspecies extrapolation or an in vitro system). The point of departure
is derived from dose-response analysis such as benchmark dose (BMD)
modeling (US EPA, 2012b) to describe a relevant response measure
representing a key event or adverse outcome; the ADJ represents an
adjustment used to align the experimental exposure regimen with the
objective human exposure scenario.
The dosimetric adjustment factor (DAF) for particles is either the
regional deposited dose ratio (RDDR) or the regional retained dose ratio
(RRDR) and constructed using factors such as the particle size dis-
tribution, exposure-speciﬁc ventilation rate and experimental ﬂow rate;
and resultant deposition fractions in the region of predicted or observed
toxicity in the human or animal respiratory tract and the in vitro system.
Additional normalizing factors used to construct the dose metric should
capture relevant mechanistic processes, for example, using a normal-
izing factor to express the deposited fraction relative to the surface area
of the respiratory tract associated with the toxicity or speciﬁc eﬀector
cells (Jarabek et al., 2005; Kuempel et al., 2015). The DAF for gases is
the regional gas dose ratio (RGDR) and is constructed similarly by
considering determinants of ADME and normalizing for mechanistic
factors related to the dose metric associated with the pathobiology in
either the POE or systemic tissues.
The choice of dosimetry model to predict either the particle or gas
DAF used to derive the HEC ranges from default to sophisticated model
structures as described (US EPA, 1994; Jarabek, 1995b; US EPA, 2012a;
Kuempel et al., 2015; Clippinger et al., 2018). Construction of the
RDDR or the RGDR depends on the level of detail and speciﬁcity of the
available data, the degree of understanding of ADME and the me-
chanism of toxicity, and should be commensurate with the biological
level of organisation of the key event or the TSE. Duration adjustment
across exposure times may be obviated if a dosimetry model is used to
simulate the exposure scenarios and describe dose metrics; otherwise
the default “C x t” adjustment and similar approaches, or more speciﬁc
adjustments based on mechanisms (e.g., use of peak concentration or
area under the curve as the internal dose metric) is used (ten Berge
et al., 1986; US EPA, 1994; Jarabek, 1995a; Rhomberg, 2009). The
conﬁdence in the type of dosimetry model used will aﬀect conﬁdence in
the translation of resultant in vitro data to the HEC and resultant risk
estimate. For example, the uncertainty factor applied to the HEC to
derive an estimate would be larger when using a default algorithm than
when using a sophisticated structure that addresses critical parameters
mechanistically (US EPA, 1994; Kuempel et al., 2015). Uncertainty
factors may also be applied to account for intra-human variability (e.g.,
the general population includes both adults and children).
Fig. 3 legend
(1) Evaluate target exposure scenario and type of inhaled agent: Target
scenario includes parameters that characterize speciﬁc population
considerations (e.g., general population, children, or occupational),
regimen (e.g., number of days per week), and duration (e.g., hours
per day and work week or lifetime). Evaluating the type of inhaled
agent requires assessment of exposure generation and character-
ization. Target scenario may also include consideration of problem
formulation or objective of the testing, including the information
requirement (e.g., identiﬁcation of intrinsic hazard properties of
chemicals or end-use products; hazard communication (i.e., classi-
ﬁcation; product labeling statements/signal words); industrial hy-
giene (e.g., short-term exposure levels or time-weighted averages);
and emergency response (e.g., egress or re-entry levels).
(2) Determine particle size distribution and density: a) Conversion of dia-
meter to aerodynamic diameter (dae) or mass median aerodynamic
diameter (MMAD) may be required (US EPA, 1994). b) Additional
physicochemical properties will help determine likely dosimetry,
such as molecular diﬀusivity; blood:air partition coeﬃcients;
reactivity including hydrolysis or to serve as an enzymatic substrate
for ADME in respiratory tract tissue; or contains structural alerts
indicative of inherent reactivity (e.g., if the chemical contains an
electrophilic center such as a carbonyl carbon in an aldehyde).
(3) Determine if human inhalation is likely: Human is presumed target
population; if evaluating or translating an in vivo animal study
would require consideration of that species' anatomy and ventila-
tion parameters. It may be possible to avoid testing if the aero-
dynamic diameter of the particle is> 100 μM (Vincent, 2005).
(4) Potential to be corrosive: All available existing information that may
be informative should be evaluated, including QSAR, read-across,
and data from in vitro assays. Evidence of skin or eye irritation or
severe pH could be used to justify waiving an LC50 study (OECD,
2014; OECD, 2017a); however, this generalization does not apply to
all chemicals as some agents with a high/low pH are not corrosive,
and not all corrosive agents will possess a high acute toxicity.
(5) Electrophile, reactive or speciﬁc toxicity or metabolism alert: If mole-
cular structure (e.g., chemical contains an electrophilic center such
as the case with an activated ester or aldehyde) indicates likelihood
of speciﬁc reactions such as hydrolysis or speciﬁc metabolism by
cells in respiratory tract, then characterization of POE toxicity is
necessary in addition to systemic toxicity.
(6) Calculate HEC for eﬀects in portal of entry (POE): Human equivalent
concentration (HEC) is calculated with diﬀerent models for parti-
cles and gases; and for respiratory versus remote or systemic eﬀects.
The choice of model also depends on data availability and ranges
from default to sophisticated model structures. The HEC calcula-
tions should use input parameters relevant to target exposure sce-
nario and potential mode of action in the respiratory tract. a) For
particles, the MPPD model is recommended and can predict re-
gional (extrathoracic, tracheobronchial, or pulmonary) deposition
to aid study design. b) For gases likely to react with tissues in the
respiratory tract, these are designated as gas Category 1 (described
in section 4b above and Table 5 of (Clippinger et al., 2018)) and
default algorithms are applied or models such as CFD or hybrid
PBPK-CFD models can reﬁne dose predictions. As indicated by the
asterisk (*), if potential for both POE and systemic toxicity exists
(e.g., systemic distribution of particles or components and gases in
Category 2) both types of toxicity must be addressed (See Steps 8a
and 8b). Guidance on the choice of model structure and necessary
data are provided in (US EPA, 1994; US EPA, 2012a; Clippinger
et al., 2018).
(7) Calculate HEC for systemic toxicity: Human equivalent concentration
(HEC) is calculated with diﬀerent models for particles and gases;
and for respiratory versus remote or systemic eﬀects. The choice of
model also depends on data availability and ranges from default to
sophisticated model structures. The HEC calculations should use
input parameters relevant to target exposure scenario and potential
mode of action for systemic toxicity, or possibly both POE and
systemic toxicity. a) For particles, the MPPD model is recommended
and can predict regional (extrathoracic, tracheobronchial, or pul-
monary) deposition to aid study design. b) For gases likely to cause
systemic toxicity, these are designated as gas Category 3 and default
algorithms are applied, or PBPK-CFD models can reﬁne dose pre-
dictions. As indicated by the asterisk (*), if potential for both POE
and systemic toxicity exists (e.g., systemic distribution of particles
or components and gases in Category 2), both types of toxicity must
be addressed (See Steps 8a and 8b). Guidance on the choice of
model structure and necessary data are provided in (US EPA, 1994;
US EPA, 2012a; Clippinger et al., 2018).
(8) Assess in in vitro system for POE eﬀects or systemic toxicity: a) Assess in
in vitro system, such as a three-dimensional human reconstructed
human lung tissue model, for POE eﬀects including respiratory ir-
ritation. See Supplementary Table 1 for potential cell systems of
interest. b) Assess in in vitro system, such as cardiac, liver, or neu-
ronal cells, for systemic toxicity. As indicated by the asterisk (*),
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consideration of dosimetry and mechanisms may require testing in
both types of systems.
Results of proof-of-concept testing based on this decision tree, the
AOPs in Table 1, and the considerations in Table 2, can be used to
inform the development of guidance for acute inhalation toxicity clas-
siﬁcation and other applications. Case study examples will be useful to
further the development and optimization of testing approaches that
will be ﬁt for regulatory decision-making (e.g., hazard classiﬁcation and
risk assessment). The following hypothetical case studies exemplify
how the above decision tree could be applied to outline a testing
strategy to assess acute inhalation toxicity. These case studies demon-
strate the utility of the decision tree for evaluating relatively simple,
well-deﬁned scenarios. However, as noted above, many real-world
human exposures are to mixtures of multiple substances and thus hy-
pothetical cases should also consider complex mixtures such as cigar-
ette smoke, cosmetic aerosols, fragrances, or air pollution. Such sub-
stances may require additional assessment that addresses the whole
aerosol as well as individual components. For consumer products, fur-
ther detailed information on tissue dose, cellular damage, and systemic
eﬀects would better inform risk assessments of potential eﬀects from
relatively low level cumulative exposures. Some speciﬁc considerations
for the development of case studies to address diﬀerent exposure sce-
narios and various inhaled agents are provided below.
a. Pesticide applicator (occupational exposure to particle)
(1) Evaluate target exposure scenario and type of inhaled agent →
Pesticide applicator in agricultural ﬁeld setting exposed to a
particulate aerosol
(2a) Determine particle size distribution and density → MMAD and
geometric standard deviation (GSD), density (ρ)
(3) Determine if human inhalation is likely → Yes, the aerodynamic
diameter of the particle is< 100 μm.
(4) Potential to be corrosive → No
(5) Electrophile, reactive or speciﬁc toxicity or metabolism alert→ No
(7a) Calculate HEC with MPPD model to predict dose for systemic
delivery and guide design → The MPPD simulation should use the
duration of exposure corresponding to an occupational scenario
(versus parameter for the general population – see below) in-
cluding the following:
Anatomy and physiology: Adult male anatomy with ventilatory
activity pattern that includes oro-nasal breathing mode at high
ventilation rate due to exertion (see (International Commission
on Radiological Protection (ICRP), 1994) and (US EPA, 1994)
for activity patterns and rates). The ventilation rate and
breathing mode diﬀerences will aﬀect the deposition pattern in
the respiratory tract, and thereby change the predicted de-
position pattern and internal systemic dose.
Exposure duration: Use a scenario speciﬁc to applicators (e.g.,
12 h spraying operation); otherwise an occupational work day
default is 8 h per day (US EPA, 1994).
Exposure regimen: Frequency of operation would dictate the
regimen (e.g., 12 h spraying operation, 5 days/week for a
growing season; otherwise, the default for a “working lifetime”
is 40 years (US EPA, 1994)) and can be considered as a con-
servative approach.
Dose metric: Dose delivered to respiratory tract or speciﬁc re-
gional surface area normalized to body weight.
(8b) Assess in in vitro system for systemic toxicity→ Evaluate assays
that query KEs relevant to the substance's mechanism of toxicity
in systemic target tissues. For example, hepatotoxicity, in vitro
basal cytotoxicity for non-neural targets, or acetyl cholinesterase
assays for neurotoxicity of a speciﬁc chemical class.
b. Reactive aldehyde gas
(1) Evaluate target exposure scenario and type of inhaled agent →
General population and gas category 1.
(2b) Determine particle size distribution and density → Calculate
molecular diﬀusivity using chemical structure as input to species-
speciﬁc CFD model to predict mass transfer, estimate a mass
transfer coeﬃcient, or use a default extraction (US EPA, 1994;
Hanna et al., 2001)
(3) Determine if human inhalation is likely → Yes
(4) Potential to be corrosive → No
(5) Electrophile, reactive or speciﬁc toxicity or metabolism alert→ Yes
(6b) Calculate HEC for extrathoracic, tracheobronchial, or pulmonary
region eﬀects of gas category 1→Use CFD or hybrid PBPK model or
default algorithm to estimate ﬂux fraction to speciﬁc region and
normalize that to surface area of region as the dose metric for the
HEC calculation. CFD and PBPK models can predict more loca-
lized delivery to speciﬁc cell types. The simulation or default al-
gorithm for HEC calculation should address the following:
Anatomy and physiology: Adults with general population venti-
lation rate.
Exposure duration: Specify the duration based on the acute ex-
posure assessment need. Emergency response derivations range
from 10min to 24 h (Vincent, 1995); an acute reference con-
centration (ARFC) is derived for 1, 4, 8, and 24 h of exposure
(Vincent, 1995); 8 h is the default for occupational exposures
(US EPA, 1994) and the US EPA Risk and Technology Review
(RTR) program uses 1 h (US EPA, 2009).
Exposure regimen: Depends on the anticipated frequency of ex-
posure.
Dose metric: Dose delivered normalized to regional surface area
(extrathoracic, tracheobronchial, or pulmonary regions) or
speciﬁc cell type.
(8a) Assess in in vitro system for POE eﬀects → Evaluate in vitro
assays relevant to mechanisms in the respiratory tract; for ex-
ample, three-dimensional reconstructed human tissue models can
be used to assess respiratory irritation (see Supplementary
Table 1).
c. VOC gas
(1) Evaluate target exposure scenario and type of inhaled agent →
General population and gas Category 3.
(2b) Determine particle size distribution and density → Determine
blood:air partition coeﬃcient and absorption fraction using PBPK
model or use default algorithm to predict absorbed fraction (US
EPA, 1994)
(3) Determine if human inhalation is likely → Yes
(4) Potential to be corrosive → No
(5) Electrophile, reactive or speciﬁc toxicity or metabolism alert→ No
(7b) Calculate HEC for systemic eﬀects of gas Category 3→Use
PBPK model or default algorithm to estimate either tissue delivery
normalized to tissue weight or systemic extraction normalized to
body weight as the dose metric for the HEC calculation. PBPK
models can predict more speciﬁc tissue doses such as those that
address metabolism. The simulation or default algorithm for HEC
calculation should address the following:
Anatomy and physiology: Adults with general population venti-
lation rate.
Exposure duration: Specify the duration based on the acute ex-
posure assessment need. Emergency response derivations range
from 10min to 24 h (Vincent, 1995). An acute reference con-
centration (ARFC) is derived for 1, 4, 8, and 24 h of exposure
(Vincent, 1995); 8 h is the default for occupational exposures
(US EPA, 1994) and the US EPA RTR program uses 1 h (US EPA,
2009).
Exposure regimen: Depends on the anticipated frequency of ex-
posure
Dose metric: Systemic blood concentration or dose delivered to
remote target tissue
(8b) Assess in in vitro system for systemic toxicity→ Evaluate assays
that query key events relevant to the substance's mechanism of
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toxicity in systemic target tissues. For example, use organ-speciﬁc
cell lines or primary cells, organ-chips, or a general cytotoxicity
assays (e.g., the 3 T3 neutral red uptake assay) in a weight-of-
evidence approach. The purpose of testing (e.g., regulatory re-
quirement or in-house screening) may inﬂuence the choice of cell
system and endpoints assessed.
5. Discussion and recommendations
This review summarizes the current state-of-the-science regarding
mechanisms of and assays available to assess acute inhalation toxicity,
including how our existing knowledge can be used to design eﬀective
non-animal testing approaches. This review was produced in response
to a recommendation from a 2016 workshop on “Alternatives
Approaches for Acute Inhalation Toxicity Testing to Address Global
Regulatory and Non-regulatory Data Requirements” (Clippinger et al.,
2018). Another recommendation of the workshop was to use the in-
formation from this review to design a proof-of-concept study to further
deﬁne the underlying mechanisms of toxicity and elucidate how the
assays may be used in an integrated approach. Results from the study
will be used to reﬁne the strategy and will be useful in continuing to
build AOPs for mechanisms of inhalation toxicity.
Moving forward, the following gaps and challenges should be ad-
dressed:
• Curate data in a user-friendly database. Data from animal and non-
animal tests have been made freely available by NICEATM in its
Integrated Chemical Environment (ICE; https://ice.ntp.niehs.nih.
gov/). ICE provides access to data for thousands of chemicals for
several acute toxicity endpoints including systemic lethality sub-
sequent to inhalation exposure. Often, publicly accessible databases
only contain LC50 data; however, some stakeholders may collect
additional information, such as the physical state of the test mate-
rial, time to death, histopathology, clinical pathology, and detailed
clinical observations. Therefore, NICEATM is working with stake-
holders from government, industry, and academia to collate re-
levant information into ICE, which can be used to build in silico
models and develop conﬁdence in in vitro approaches.
• Evaluate existing and develop new QSAR models. Few QSAR models
are currently available that can be applied to predicting inhalation
toxicity. Modellers should interrogate the applicability domain of
any QSAR (e.g., TOPKAT, REACH Across, and MultiCASE) to identify
whether the model might be optimized for predicting inhalation
toxicity. This could be accomplished via a partnership between
modellers and companies that can provide test compounds. Such an
approach could be used to identify advantages and gaps of existing
models and clarify which models could be used for speciﬁc applic-
ability domains. Additionally, data collected in ICE and other
sources could be used to develop new models. The U.S.
Environmental Protection Agency National Center for
Computational Toxicology's Chemistry Dashboard (https://
comptox.epa.gov/dashboard/) could serve as a convenient plat-
form to house available models and their predictions. Importantly,
government funding must be allocated for in silico model develop-
ment and evaluation. It will also be important to ensure the varia-
bility associated with the in vivo data being relied upon for new
model development is carefully evaluated so that the uncertainties
associated with the model predictions can be quantiﬁed. A public-
private partnership involving>50 participants is currently devel-
oping best practices protocols for in silico method development re-
levant to a wide range of endpoints (Myatt et al., 2018).
• Advance mechanistic dosimetry models for IVIVE. Advancing model
structures to address the range of physicochemical characteristics
and compiling reliable input data on critical parameters (e.g., ex-
posure proﬁles, physicochemical properties, ventilation activity
patterns, cell characteristics, and ADME) will facilitate quantitative
IVIVE to support decision-making and assessment purposes.
Mechanistic models are necessary to describe inhalation dosimetry
to predict target human exposures as well as kinetic characteristics
for diﬀerent test systems. Such models should be available as open
access to facilitate their application. Data to support evaluation of
dose metrics to describe the TSE at various levels of observation
(e.g., subcellular) are necessary to characterize MIE and KE in var-
ious AOPs.
• Develop and share AOPs. There are numerous AOPs relevant to in-
halation exposures (Table 1). However, these AOPs need to be fur-
ther developed and additional AOPs must be added to speciﬁcally
address outcomes that are likely following inhalation exposures.
Identiﬁcation of key events can aid the development of AOPs and is
critical to construction of IATAs. AOPs can be used to identify ap-
propriate in silico and in vitro tests to be used in an IATA to assess a
substance's likelihood of causing a speciﬁc adverse outcome and
build conﬁdence in the use of in vitro assays to characterize the key
events. Researchers should collaborate on the development of AOPs;
for example, through the use of the AOP Wiki, which was created to
provide an interactive and virtual platform for AOP development
and to promote international consensus on the developed AOPs. It is
particularly important that subject matter experts connect with AOP
experts so that these pathways include relevant and necessary in-
formation in the proper format. Funding must also be made avail-
able to researchers developing AOPs and conducting in vitro testing
to ﬁll in knowledge gaps.
• Optimize in vitro test systems. Numerous systems can be used to
assess the toxicity of inhaled test substances (Supplementary
Table 1); however, optimization of the systems is needed. For ex-
ample, although not unique to the inhalation route of exposure,
there is a need to characterize the ability of cell-based systems to
metabolize compounds, because metabolism can inﬂuence toxicity.
Although in vitro test systems lacking metabolic capacity can eﬀec-
tively screen for biological eﬀects of the parent chemical, the
pharmacokinetic relationship between exposure and concentration
at a target site needs to be evaluated. In particular, the metabolic
activity of three-dimensional tissue and lung-on-a-chip models
should be characterized. These models are considered to represent
human biology, but cannot be uniformly representative unless they
can account for metabolic activity. Standardized test protocols must
also be developed to promote consistency across laboratories.
Experimental designs should consider dosimetry and human-re-
levant exposure conditions. Inter-disciplinary collaboration, for ex-
ample between experts in exposure science and tissue culture,
should be incorporated into activities surrounding protocol devel-
opment. In addition to the acute inhalation toxicity workshop dis-
cussed in this paper (Clippinger et al., 2018), an example of cross-
sector collaboration is the recent workshops hosted by the Institute
for In Vitro Sciences, speciﬁc to inhaled tobacco products. These
workshops have included industry, academic, government, and non-
governmental organisations to discuss the development, standardi-
zation, and harmonization of in vitro methods for next generation
tobacco product and e-cigarette testing (Behrsing et al., 2016;
Behrsing et al., 2017).
• Design and test integrated approaches. Use of the above in-
formation—existing data, AOPs, non-testing approaches, and in vitro
assays—will be needed to design a comprehensive testing approach
for acute inhalation toxicity. To ensure all needs are met and to
facilitate implementation, experts with diverse expertise (e.g., in
vitro and in vivo inhalation toxicology, computational modeling,
exposure science) from diﬀerent sectors (regulatory, non-regulatory
governmental organisations, industry, academic, and non-govern-
mental organisations) should collaborate on the design of these
approaches. A key step in this process will be proof-of-concept
testing focused on a speciﬁc chemical space, such as agrochemicals,
air toxics, tobacco, or pharmaceuticals, coupled with elucidating
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key events of the pathogenesis for a speciﬁc AOP, which will be
useful both to obtain toxicity data and to demonstrate the validity of
this approach. The knowledge gained from this eﬀort can then be
applied to the design of testing strategies for other substances, as
there will be similarities and diﬀerences in the approaches used for
diﬀerent chemistries. A list of reference chemicals can be developed
based on the available in vivo data (rat, human, and/or other spe-
cies) so that non-animal approaches can be retrospectively vali-
dated, while keeping in mind that non-human test results often do
not reﬂect what happens in humans. Results from the proof-of-
concept testing can be used to standardize test protocols and further
develop AOPs.
The development, implementation, and global regulatory accep-
tance of non-animal approaches for acute inhalation toxicity testing is
an ambitious but attainable goal, with success necessitating collabora-
tion among diverse stakeholders. The PETA International Science
Consortium and NICEATM are coordinating working groups to ac-
complish the tasks above and researchers who wish to become involved
in these activities are encouraged to participate. Success in this area
will produce models and test systems capable of predicting both acute
lethality and local eﬀects caused by inhalation exposures. These new
approaches have the potential to better protect human health by using
21st century science rooted in contemporary understanding of human
mechanisms of toxicity without using animals.
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